Physician profile
Michael E Madison
NPI 1093866147
$1,573.21
in general payments reported to CMS, 2019-2025
24 companies · $188 in 2025
The $188 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $70.43 · 2021: $114 · 2022: $91.88 · 2023: $351 · 2024: $577 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,100 · Education: $16.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,100.33 |
| Education | $16.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $348.79 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $174.03 | 2024-2025 | Entyvio |
| Alkermes, INC. | $163.77 | 2019-2021 | |
| Celltrion USA INC. | $136.85 | 2024-2025 | Vegzelma, Zymfentra |
| Janssen Biotech, INC. | $120.06 | 2023-2024 | Stelara, Tremfya, Simponi |
| Aimmune Therapeutics, INC. | $99.71 | 2024-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $79.84 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $73.50 | 2020-2023 | Nuedexta |
| Gilead Sciences, INC. | $58.11 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $39.13 | 2024-2025 | Voquezna |
| Lundbeck LLC | $37.45 | 2021 | |
| Eisai INC. | $33.77 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $33.34 | 2021-2022 | |
| Indivior INC. | $21.45 | 2024 | Sublocade |
| Corium, LLC | $19.72 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $16.69 | 2024 | Brixadi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.45 | 2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.09 | 2023 | Cyltezo |
| Shire North American Group INC | $15.51 | 2019 | |
| Ferring Pharmaceuticals INC. | $15.15 | 2023 | Rebyota |
| Hikma Pharmaceuticals USA | $14.78 | 2022 | |
| Pfizer INC. | $13.25 | 2023 | |
| Vanda Pharmaceuticals INC. | $12.97 | 2019 | |
| Orexo US, INC. | $12.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Madison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.